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Copy number variants (CNVs) are DNA sequence alterations, resulting in gains (duplications) and losses (deletions) of genomic
segments. They often overlap genes and may play important roles in disease. Only one published study has examined CNVs in
late-onset Alzheimer’s disease (AD), and none have examined mild cognitive impairment (MCI). CNV calls were generated in 288
AD, 183 MCI, and 184 healthy control (HC) non-Hispanic Caucasian Alzheimer’s Disease Neuroimaging Initiative participants.
After quality control, 222 AD, 136 MCI, and 143 HC participants were entered into case/control association analyses, including
candidate gene and whole genome approaches. Although no excess CNV burden was observed in cases (AD and/or MCI) relative
to controls (HC), gene-based analyses revealed CNVs overlapping the candidate gene CHRFAM7A, as well as CSMD1, SLC35F2,
HNRNPCL1, NRXN1, and ERBB4 regions, only in cases. Replication in larger samples is important, after which regions detected
here may be promising targets for resequencing.
1. Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia and accounts for 50–80% of dementia cases.
Currently, an estimated 5.3 million Americans have AD, the
seventh leading cause of death in the United States. The
hallmark abnormalities of AD are deposits of the protein
fragment amyloid β (plaques) and twisted strands of the
protein tau (tangles). Amnestic mild cognitive impairment
(MCI) is a clinical condition in which a person has problems
with memory, with or without other cognitive deficits, that
are noticeable to others and show up on psychometric testing
but are not severe enough to interfere significantly with daily
functioning. About 14–18% of individuals aged 70 years and
older have MCI, and these individuals are likely to progress
to dementia, particularly AD, with an annual conversion rate
of 10–15% [1].
Genetic factors play a key role in the development and
progression of AD. AD has a high heritability, with 58–79%
of phenotypic variation estimated to be caused by genetic
factors [2]. Early-onset AD (onset < 65 years) accounts for
a small percentage (<5%) of cases and is primarily caused
by mutations in three genes that affect the cerebral levels
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of amyloid β peptide: AβPP (amyloid-β protein precursor)
on chromosome 21, PSEN1 (presenilin 1) on chromosome
14, and PSEN2 (presenilin 2) on chromosome 1 [3]. Late-
onset AD (LOAD) accounts for the majority of AD cases,
but only the e4 allele of the APOE (apolipoprotein E)
gene on chromosome 19 has been consistently replicated
across studies. Recently, three large genome-wide associa-
tion studies (GWASs) identified five additional loci: CLU
(clusterin), CR1 (complement component (3b/4b) receptor
1), PICALM (phosphatidylinositol binding clathrin assembly
protein), BIN1 (bridging integrator 1), and EXOC3L2 (exo-
cyst complex component 3-like 2) to be strongly associated
with AD [4–6]. These loci also showed strong association
in replication studies [7], further supporting a role in AD
susceptibility.
Copy number variants (CNVs) are segments of DNA,
ranging from 1 kilobase (kb) to several megabases (Mb), for
which differences in the number of copies have been revealed
by comparison of two or more genomes. These differences
can be copy number gains (duplications or insertional
transpositions), losses (deletions), gains or losses of the same
locus, or multiallelic or complex rearrangements. CNVs
have been implicated in various neuropsychiatric disorders
such as autism and schizophrenia [8]. To date, the role of
CNVs in LOAD has only been examined in one study [9].
These authors performed a genome-wide scan of AD in 331
dementia cases (in which >80% of patients had a clinical
diagnosis of AD) and 368 controls. Although no CNVs,
which are typically rare occurrences, were significant at
genome-wide threshold, Heinzen et al. were able to identify
a duplication in the CHRNA7 gene warranting further
investigation. To date, no study has looked at the role of
CNVs in MCI.
In the present report, we conducted a preliminary CNV
analysis using genotype data from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) cohort to examine the role
of CNVs in susceptibility to MCI and LOAD. ADNI is an
ongoing multiyear public-private partnership to test whether
serial magnetic resonance imaging (MRI), positron emission
tomography (PET), genetic factors such as single nucleotide
polymorphisms (SNPs) and CNVs, other biological markers,
and clinical and neuropsychological assessments can be
combined to improve early diagnosis and predict progression
of MCI and early AD. Here, we used the genome-wide array
data acquired on the ADNI cohort to determine whether AD
and MCI participants (cases) showed an excess burden of
CNVs relative to controls and to characterize any genomic
regions where CNVs were detected in cases but not controls.
2. Materials and Methods
2.1. Alzheimer’s Disease Neuroimaging Initiative. The ADNI
was launched in 2004 by the National Institute on Aging
(NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies, and nonprofit
organizations, as a $60 million, multiyear public-private
partnership. The Principal Investigator of this initiative is
Michael W. Weiner, M.D., VA Medical Center and University
of California—San Francisco. ADNI is the result of efforts
of many coinvestigators from a broad range of academic
institutions and private corporations. Presently, more than
800 participants, aged 55 to 90, have been recruited
from over 50 sites across the US and Canada, including
approximately 200 cognitively normal older individuals
(i.e., healthy controls or HCs) to be followed for 3 years,
400 patients diagnosed with MCI to be followed for 3
years, and 200 patients diagnosed with early AD to be
followed for 2 years [10]. Longitudinal imaging, including
structural 1.5T MRI scans collected on the full sample and
[11C]PiB- and [18F]FDG-PET imaging on a subset, and
performance on neuropsychological and clinical assessments
were collected at baseline and at followup visits in 6–
12-month intervals. Other biomarkers are also available
including APOE and whole genome genotyping on the full
ADNI sample, and longitudinal cerebrospinal fluid (CSF)
markers on a subset of the sample. Written informed consent
was obtained from all participants, and the study was
conducted with prior institutional review boards approval.
Further information about ADNI can be found in [11] and
at http://www.adni-info.org.
2.2. Participants. Participants in the present report included
655 non-Hispanic Caucasian individuals from the ADNI
cohort who had DNA samples extracted from peripheral
blood. Those with DNA samples derived from cell lines
were excluded from the present analysis because cell line
transformation might influence CNV results [12, 13]. Cur-
rent diagnoses were downloaded from the ADNI database
as of 04/29/2010 (AD = 288, MCI = 183, HC = 184). In
addition to AD participants who had a baseline and current
diagnosis of AD, we included MCI participants who had
converted from a baseline diagnosis of MCI to a current
diagnosis of AD (MCI Converters) as well as one participant
who had converted from a baseline diagnosis of HC to
a current diagnosis of AD in the AD group. Similarly,
in addition to MCI participants who had a baseline and
current diagnosis of MCI, we included seven HC participants
who had converted from a baseline diagnosis of HC to a
current diagnosis of MCI in the MCI group. Data used in
preparation of this report is publicly available on the ADNI
web site (http://loni.ucla.edu/ADNI/). The focus of ADNI is
on incident LOAD. To our knowledge, no participants in the
present study carry a known causal mutation [14].
2.3. Genotyping. Blood samples from each participant were
obtained and sent to Pfizer for DNA extraction and were
also banked at The National Cell Repository for Alzheimer’s
Disease (NCRAD; http://ncrad.iu.edu/). Genotyping was
performed by the Translational Genomics Research Institute
(TGen) (Phoenix, AZ) using the Illumina Human610-Quad
BeadChip as previously described [15, 16]. As indicated by
the manufacturer’s documentation, the Human610-Quad
BeadChip contains 620,901 markers. This array provides
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dense genomic coverage (89%) in the CEU (Utah residents
with Northern and Western European ancestry from the
Centre d’Etude du Polymorphisme Humain (CEPH) col-
lection) population analyzed here with a median marker
spacing of 2.7 kb. In addition, 27,635 markers are included
in “unSNPable” regions likely to contain CNVs that are not
easily assessed by SNPs. Coverage is provided for 3,938 CNV
regions (184,064 markers) reported in the Toronto Database
of Genomic Variants (http://projects.tcag.ca/variation/) at
an average of 37.7 markers per region. Markers have an
average of 15–18-fold redundancy to improve signal quality
for detection of CNVs (mean Log R Ratio SD < 0.2, see
below).
Normalized bead intensity data for each sample was
loaded into GenomeStudioV2009.1 software (Illumina, Inc.,
CA) along with the manufacturer’s cluster file to generate
SNP genotypes. The Log R Ratio (LRR) and B Allele
Frequency (BAF) values computed from the signal intensity
files by GenomeStudio for each sample were exported and
used for the generation of CNV calls. Initial genotyping was
performed by TGen using BeadStudio software (Illumina,
Inc., CA). In January 2010, we reprocessed the array data
using GenomeStudioV2009.1, and this data set will be made
available on the ADNI website in a followup data release.
2.4. Inference of LRR and BAF. The two alleles of an SNP are
designated as allele A and allele B. GenomeStudio software
uses a five-step six-degree of freedom affine transformation
to normalize signal intensity values of the A and B alleles
(referred to as X and Y). The normalized values are then
transformed to a polar coordinate plot of normalized
intensity R = Xnorm + Ynorm and composition (copy angle)
θ = (2/pi) ∗ arctan (Ynorm/Xnorm), where Xnorm and Ynorm
represent transformed normalized signals from alleles A
and B for a particular locus (Illumina’s genotyping data
normalization methods white paper). The LRR value for a
sample is calculated as follows:
LRR = log2(normalized R value/expected R value) for the
SNP.
Linear interpolation of the R value at the SNP’s θ value
for a sample, relative to the R values of the surrounding
clusters, is used to compute the expected R value.
The BAF for a sample shows the θ value for an SNP,
corrected for cluster positions, which were generated from
a large set of previously studied normal individuals. BAF is
described by the following equation:
BAF = 0 if θ < θAA
= 0.5∗ (θ − θAA)
(θAB − θAA) if θ < θAB
= 0.5 + 0.5∗ (θ − θAB)
(θBB − θAB) if θ < θBB
= 1 if θ ≥ θBB,
(1)
where θAA = mean θ value of all genotypes in AA cluster
plotted in polar normalized coordinates, θAB = mean θ value
of all genotypes in AB cluster plotted in polar normalized
coordinates, and θBB = mean θ value of all genotypes in BB
cluster plotted in polar normalized coordinates (GenomeS-
tudio Genotyping Module v1.0 User Guide).
2.5. Generation of CNV Calls and Quality Control. CNV
calls were generated for the 655 non-Hispanic Caucasian
participants whose DNA was derived from periph-eral
blood. PennCNV software (2009Aug27 version) (http://
www.openbioinformatics.org/penncnv/), which implements
a hidden Markov model (HMM) [17], was used to generate
the CNV calls. The hg18 “all” PennCNV hidden Markov
model (hmm), population frequency of B allele (pfb), and
gcmodel files were used to ensure that CNV-specific markers
were included. All samples were subjected to extensive
quality control (QC). Since samples that have below optimal
genomic wave QC values can be considered unreliable
[18], we applied the GC-model wave adjustment procedure,
using PennCNV’s gcmodel file. A frequency distribution
plot of the number of CNV calls for all samples was
made, and samples were excluded if the number of CNV
calls made for that individual was greater than the 90th
percentile of the frequency distribution. One sample was
observed to have multiple deletions and duplications on
chromosome 18 (Supplementary Figure 1 in Supplementary
Materials available Online at doi:10.4061/2011/729478) and
was excluded from further analysis as it may be a mosaic
sample [19]. Samples were also excluded if they met the
following criteria: LRR SD > 0.35, BAF Drift > 0.002, or
Waviness Factor (WF) >0.04. The LRR SD is a measure
of signal-to-noise ratio. Sometimes, when a sample has
genotyping failure, many SNP markers will have abnormal
BAF patterns (i.e., they do not cluster to 0, 0.5, or 1), yet their
LRR looks normal. The BAF Drift takes into account these
abnormal BAF patterns. The WF measures the waviness of
the signal curves, as artificial gains and losses in the genome
can be created by peaks and troughs of the wave.
Analyses were also restricted to autosomes due to the
complications of hemizygosity in males and X-chromosome
inactivation in females. Finally, to ensure only high-confi-
dence CNVs were included in the analysis, CNVs for which
the difference of the log likelihood of the most likely copy
number state and less likely copy number state was less than
10 (generated using the confidence function in PennCNV),
CNVs that were called based on data from fewer than 10
SNPs, and CNVs that had >50% overlap with centromeric,
telomeric, and immunoglobulin regions as defined in Need
et al. [20] were excluded. 501 participants (AD = 222, MCI
= 136, HC = 143) passed all QC checks and were included in
further CNV analyses.
2.6. Case/Control Association Analyses. Case/control associ-
ation analyses using CNV calls generated for the AD, MCI,
and HC participants were performed using PLINK v1.07 [21]
(http://pngu.mgh.harvard.edu/purcell/plink/) to investigate
any differences in CNV calls between cases and controls (AD
versus HC; MCI versus HC). Two approaches were used:
(1) a candidate gene approach using AD genes, identified
from the AlzGene database [22] (http://www.alzgene.org/)
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Figure 1: Examples of candidate genes (a) CHRFAM7A and (b) LRRTM3, overlapped by CNV calls from at least one Alzheimer’s disease
and/or one mild cognitive impairment participant, but no healthy controls. The red rectangles represent deletions, and the blue rectangles
represent duplications (March 2006 (NCBI36/hg18) assembly).
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Figure 2: Representative image of B Allele Frequency and Log R Ratio of the participant who had a duplication at 16p11.2. The purple-
shaded portion indicates the duplicated region (Human Genome Build 36.1).
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as having a positive association with AD in at least one
study, consisting of 294 genes as of 04/22/2010, and (2)
a whole genome approach using PLINK’s entire gene list
(hg18 coordinates), consisting of 17,938 genes. The AlzGene
database provides a comprehensive and regularly updated
synopsis of genetic studies in AD. In both approaches, CNV
segments either partially or completely overlapping gene
regions were analyzed. Both deletions and duplications were
included in the analyses.
Representative plots of CNV calls (Figure 1) were gen-
erated in UCSC Genome Browser (http://genome.ucsc.edu/)
[23] (March 2006 (NCBI36/hg18) assembly). Plots were
produced using the genome browser track for the Illumina
Human-610 array obtained from the PennCNV website.
Representative plots of LRR and BAF values for samples
(Figure 2, Supplementary Figures 1 to 3) were generated
using the Illumina Genome Viewer plugin within GenomeS-
tudio (Human Genome Build 36.1).
3. Results
3.1. Description of CNV Calls by Current Diagnostic Group.
The sample demographics and CNV call characteristics of
the 501 participants who passed all QC checks are shown in
Tables 1 and 2. A total of 6,737 CNV calls (4,746 deletions
and 1,991 duplications) were observed in these participants.
The average number of SNPs per CNV call was 25 and the
average length of a CNV call was 105.93 kb. A higher CNV
call rate and a lower average CNV call size were observed
in deletions compared to duplications. On comparing the
three diagnostic groups, AD and MCI participants appeared
to have a higher CNV call rate for deletions and a lower
CNV call rate for duplications, but these were not statistically
significant (P < .05) when evaluated by permutation. We
also evaluated whether CNV burden was higher in cases
than controls in the APOE e4 negative participants. There
was a similar trend toward a higher CNV call rate for
deletions and lower CNV call rate for duplications in
AD and MCI participants, but these were not statistically
significant (P < .05; data not shown). A large proportion
of deletions and duplications were found in the 0.1–0.5 Mb
size range (Table 3). Two AD participants were found to
have very large CNV calls (>2 Mb) (Supplementary Figures 2
and 3). One AD participant had a deletion on chro-
mosome 4 (Supplementary Figure 2), which includes the
following genes: NDST4 (N-deacetylase/N-sulfotransferase
4), TRAM1L1 (translocation-associated membrane protein
1-like 1), and MIR1973 (microRNA 1973). The other AD
participant had a duplication on chromosome 11 (Supple-
mentary Figure 3), which includes the gene LUZP2 (leucine
zipper protein 2).
3.2. Case/Control Association Analyses
3.2.1. Candidate Gene Approach. We identified regions over-
lapping 294 AD candidate genes with CNV calls from at
least one case (AD and/or MCI) but no controls (HC).
As expected, cell sizes were very small in each group
leading to low power. Resulting CNV calls along with APOE
genotype and age at onset (for the AD at baseline group)
are presented in Table 4 for reference although these did
not meet conventional significance (P < .05). A number of
genes, such as CHRFAM7A (CHRNA7 (cholinergic receptor,
nicotinic, alpha 7, exons 5–10) and FAM7A (family with
sequence similarity 7A, exons A–E) fusion), had CNV calls
from only AD or MCI participants partially overlapping
them. Figure 1 shows representative plots of two of these
genes (CHRFAM7A and LRRTM3).
3.2.2. Whole GenomeApproach. We also identified CNV calls
present in cases (AD and/or MCI) but not controls (HC)
within regions overlapping 17,938 genes. There was no sig-
nificant (P < .05) gene after correction for multiple testing.
We, therefore, focused on genes that had an uncorrected P <
.05. The genes identified included CSMD1 (CUB and Sushi
multiple domains 1), HNRNPCL1 (heterogeneous nuclear
ribonucleoprotein C-like 1), and SLC35F2 (solute carrier
family 35, member F2) (Table 5). We also observed CNVs
overlapping two genes associated with neuropsychiatric
disorders: NRXN1 (neurexin 1) [24, 25] and ERBB4 (v-erb-a
erythroblastic leukemia viral oncogene homolog 4 (avian))
[26], but these did not reach significance (P < .05). An MCI
participant, who subsequently converted to clinical AD, was
also observed to have a duplication comprising 23 genes in
the 16p11.2 region (Figure 2).
4. Discussion
The present report represents an initial analysis of CNVs in
the ADNI dataset and is the first CNV analysis of patients
with MCI. After extensive QC, we analyzed CNV calls
generated in cases (AD and MCI) compared to controls
(HC), using whole genome and candidate gene association
approaches.
Comparison of the CNV calls between the three diag-
nostic groups showed no excess CNV burden (rate of calls)
in AD and MCI participants compared to controls. This
is consistent with previously published results [9]. Two
AD participants were found to have CNV calls >2 Mb.
One AD participant had a duplication on chromosome 11
(Supplementary Figure 3) which includes the gene LUZP2
(leucine zipper protein 2). This gene has been shown to be
expressed only in the brain and spinal cord in adult mouse
tissues [27]. The authors of the study also found this gene
to be deleted in some patients with Wilms tumor-aniridia-
genitourinary anomalies-mental retardation (WAGR) syn-
drome. Another AD participant had a deletion on chro-
mosome 4 (Supplementary Figure 2), which includes the
following genes: NDST4 (N-deacetylase/N-sulfotransferase
4), TRAM1L1 (translocation-associated membrane protein
1-like 1), and MIR1973 (microRNA 1973). None of these
genes have been previously associated with AD susceptibility.
Further investigation by either cytogenetic techniques such
as fluorescence in situ hybridization (FISH) or molecular
biology techniques such as real-time quantitative polymerase
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Table 1: Sample demographics.
Current diagnosis Alzheimer’s disease Mild cognitive impairment Healthy controls P value
Number of participants 222 136 143 —
Gender (Males/Females) 133/89 87/49 82/61 not significant
Baseline age (Mean ± SD) 75.10± 7.27 75.88± 7.17 75.83± 5.32 not significant
Years of education (Mean ± SD) 15.30± 3.05 15.85± 3.01 16.24± 2.62 0.009
APOE group (e4 negative/e4 positive) 73/149 70/66 108/35 <0.001
Age of onset (Mean ± SD) 74.08± 7.73 — — —
Table 2: Characteristics of CNV calls in the three diagnostic groups.
Alzheimer’s disease
(n = 222)
Mild cognitive impairment
(n = 136) Healthy controls (n = 143)
Deletions:
Number of CNVs 2128 1340 1278
Rate per participant 9.59 9.85 8.94
Average size (kb) 73.24 76.32 79.38
Duplications:
Number of CNVs 886 498 607
Rate per participant 3.99 3.66 4.24
Average size (kb) 157.24 154.06 170.30
chain reaction (PCR) and deep resequencing is required to
determine the clinical relevance of these regions.
A case/control association analysis was then performed
using a candidate gene approach and a whole genome
approach to determine if there was an excess of CNV
calls partially overlapping genes in AD or MCI par-
ticipants relative to controls, suggesting potential in-
volvement of these genes in AD or MCI susceptibil-
ity.
The candidate gene approach revealed several interesting
genes (Table 4 and Figure 1). The CHRFAM7A gene had
CNV calls in cases (two AD and two MCI) but not in
controls. CHRFAM7A, located on chromosome 15, consists
of a partial duplication of the CHRNA7 (cholinergic receptor,
nicotinic, alpha 7) gene (exons 5-10) fused to a copy of the
FAM7A (family with sequence similarity 7A) gene (exons
A-E) [28]. The CHRFAM7A gene contains a polymorphism
consisting of a 2-base pair deletion (−2 bp) at position 497-
498 of exon 6. This−2 bp polymorphism has been associated
with schizophrenia [29]. The CHRFAM7A genotype without
the −2 bp allele has also been shown to be significantly
overrepresented in AD (P = .011), dementia with Lewy
bodies (P = .001), and Pick’s disease (P < .0001) participants
[30]. Heinzen et al. found a duplication in six out of
276 dementia cases (2%) and one out of 322 controls
(0.3%) within the schizophrenia and epilepsy-associated risk
region at 15q13.3, affecting the CHRNA7 gene [9]. In the
present study, we found a deletion in one out of 222 AD
participants (0.45%) and one out of 136 MCI participants
(0.74%), as well as a duplication in two out of 143 HC
participants (1.40%). This gene codes for one of several
neuronal cholinergic nicotinic receptors. Genetic variants in
CHRNA7 and other cholinergic receptor genes have been
implicated in AD susceptibility [9], and further investigation
of this gene family is warranted. The number of CNV
calls overlapping the identified genes is small, as we had
a small sample size (n = 501) after QC for analysis limiting
power. Nevertheless, all identified genes have been previously
investigated in AD studies and thus represent potential
candidate genes. Replication studies with larger sample sizes
as well as laboratory validation are required to confirm the
role of these genes in AD susceptibility.
The whole genome approach revealed three genes at
uncorrected P < .05, as shown in Table 5. CSMD1 (CUB
and Sushi multiple domains 1) has been shown to be
primarily synthesized in the developing central nervous
system (CNS) and epithelial tissues [31]. It is enriched in the
nerve growth cone, suggesting that it may be an important
regulator of complement activation and inflammation in
the developing CNS. HNRNPCL1 (heterogeneous nuclear
ribonucleoprotein C-like 1) is predicted to play a role in
nucleosome assembly by neutralizing basic proteins such as
A and B core hnRNPs (Uniprot: http://www.uniprot.org/).
SLC35F2 (solute carrier family 35, member F2), also known
as lung squamous cell cancer-related protein LSCC-3, is
integral to membrane and transport (Gene Ontology:
http://www.geneontology.org/).
We also identified CNVs overlapping two candidate
genes associated with neuropsychiatric disorders: NRXN1
and ERBB4, from the whole genome approach in cases,
but not in controls. Deletions in the NRXN1 (neurexin
1) gene were observed in four AD participants and three
MCI participants; deletions in the ERBB4 (v-erb-a ery-
throblastic leukemia viral oncogene homolog 4) gene were
observed in four AD participants and one MCI participant,
respectively. NRXN1, a member of the neurexin family on
chromosome 2, is a cell surface receptor that binds neu-
roligins. The Ca2+-dependent neurexin-neuroligin complex
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Table 3: Participants grouped by CNV call size.
Call size
Alzheimer’s
disease
(n = 222)
Mild cognitive
impairment
(n = 136)
Healthy controls
(n = 143)
Deletions n (%) Duplications n (%) Deletions n (%) Duplications n (%) Deletions n (%) Duplications n (%)
0.1–0.5 Mb 174 (78.38) 183 (82.43) 104 (76.47) 100 (73.53) 114 (79.72) 120 (83.92)
0.5–1.0 Mb 6 (2.70) 27 (12.16) 8 (5.88) 18 (13.24) 8 (5.94) 27 (18.88)
1.0–1.5 Mb 0 (0.00) 8 (3.60) 0 (0.00) 4 (2.94) 2 (1.40) 8 (5.59)
1.5–2.0 Mb 0 (0.00) 2 (0.90) 0 (0.00) 1 (0.74) 1 (0.70) 0 (0.00)
>2.0 Mb 1 (0.45) 1 (0.45) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Table 4: Genes that have CNV calls from at least one Alzheimer’s disease (AD) and/or one mild cognitive impairment (MCI) participant
and no healthy controls using the candidate gene approach.
Chromosome Region Start (bp) End (bp)
Number of
AD
participants
APOE
genotype
Age at onseta
Number of
MCI
participants
APOE
genotype
5 PPP2R2B 145949260 146441226 1 e3/e3 N/A 0 —
6 ATXN1 16407321 16869700 1 e3/e4 83 years 0 —
7 MAGI2 77484309 78920826 1 e2/e4 N/A 0 —
7 RELN 102899472 103417198 0 — — 1 e4/e4
9 GRIN3A 103371455 103540683 1 e3/e3 74 years 0 —
10 LRRTM3 68355797 68530873 1 e3/e3 55 years 0 —
10 LIPA 90963305 91001640 0 — — 1b e3/e3
12 PPM1H 61324030 61614932 1 e2/e3 N/A 1 e2/e3
15 CHRFAM7A 28440734 28473156 2 e3/e3 N/A 2 e3/e3
e3/e4 N/A e3/e4
15 ADAM10 56675801 56829469 1 e3/e3 N/A 1b e3/e3
21 DNAJC28 33782107 33785893 1 e3/e4 74 years 0 —
21 DOPEY2 36458708 36588442 0 — — 1 e3/e4
22 GSTT1 22706138 22714284 1 e3/e3 59 years 0 —
a
Age at onset of AD symptoms, available only for participants with a baseline diagnosis of AD; N/A: Not available.
bThe same participant had CNV calls overlapping the two genes.
is present in the CNS at synapses and is required for efficient
neurotransmission and formation of synaptic contacts [32].
This gene has been found to have reduced expression with
AD severity [33], and its disruption has been shown to
be associated with schizophrenia [20, 25, 34] and autism
[24, 35]. Deletions in this gene have also been shown
to predispose to a variety of developmental disorders
including autism spectrum disorders, language delays, and
mental retardation [36]. Interestingly, an SNP (rs6463843)
flanking the NXPH1 (neurexophilin 1) gene was identified
by our group in a GWAS of neuroimaging phenotypes
in the ADNI cohort [37]. The NXPH1 gene, a member
of the neurexophilin family, forms a tight complex with
alpha neurexins, and the SNP was found to be associated
with reduced global and regional grey matter density.
The ERBB4 gene, also on chromosome 2, is a member
of the type I receptor kinase subfamily, that encodes a
receptor for neuregulin 1 (NRG1). The neuregulin-ErbB
receptor signaling pathway plays a role in development,
synaptic function, and neural network activity and has been
implicated in schizophrenia [38]. One AD participant had
a large duplication that included 23 genes in the 16p11.2
region (Figure 2). CNVs in this region have previously
been associated with autism [39–41], schizophrenia [42],
cognitive impairment and speech/language delay [43], and
obesity [44, 45], but not AD or MCI. Because the ADNI
employed a case/control design, DNA from family members
was not available for linkage analysis. This limitation pre-
cluded determination as to whether CNVs were de novo or
inherited.
The ADNI cohort provides a unique opportunity for
discovery analyses such as this initial CNV analysis. With
multiple types of potential biomarkers, including structural
and molecular imaging, blood and CSF markers, genetic
information, and behavioral data, analysis of the ADNI data
has the potential to enhance knowledge of the underlying
mechanisms leading to MCI and to AD.
The present study has several limitations related to
participant inclusion and exclusion and the software and
algorithms used in the analyses. CNV calls in the present
report were generated from DNA samples derived only from
peripheral blood-78 participants whose DNAs were derived
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Table 5: Significant (uncorrected P < .05, relative to healthy controls) genes present in either Alzheimer’s disease (AD) and/or mild cognitive
impairment (MCI) participants, but not healthy controls using the whole genome approach.
Chromosome Region Start (bp) End (bp) Number of AD calls P value for AD calls Number of MCI calls P value for MCI calls
8 CSMD1 2780281 4839736 9 0.0114 4 0.0556
1 HNRNPCL1 12829847 12831165 6 0.0493 4 0.0549
11 SLC35F2 107166926 107234864 5 0.0820 6 0.0120
from lymphoblastoid cell lines (LCLs) were excluded. LCLs
are generated by transforming peripheral B lymphocytes
by the Epstein-Barr virus (EBV). EBV-transformed cells are
shown to have significant telomerase activity and develop
aneuploidy, along with other cellular changes such as gene
mutations and reprogramming in the postimmortal cellular
stage of transformation [13]. Thus, to avoid CNV call
discrepancies that may arise between the different DNA
sources, we chose to include only those participants whose
DNA was derived from peripheral blood. Additional QC was
also performed, resulting in only 501 samples that passed
all QC checks. To date, no definitive QC criterion has been
established to ensure only high-quality samples are included
in CNV analyses. Therefore, the QC criterion applied in
the present study may have been too stringent leading to
the exclusion of samples which otherwise may have had
informative CNV data. In future studies, we propose to
analyze multiple QC thresholds to determine the optimum
QC criteria.
Another limitation is that the CNV calls analyzed in
the current study were generated using only one software
program (PennCNV). Several detection algorithms includ-
ing HMMs, segmentation algorithms, t-tests, and standard
deviations of the LRR are available for identifying CNVs
from genome-wide SNP array data. A comparison of these
methods has been performed by Dellinger et al. Even though
the PennCNV program was found to have moderate power in
detecting CNVs, it also had a low false positive call rate. The
program was found to detect less CNV calls in comparison to
other methods and did not accurately detect small CNVs (3-4
SNP CNVs) [46]. However, in our analyses, we have included
CNV calls that had at least 10 SNPs. Obtaining the same CNV
calls from another algorithm would help further reduce false
positive CNV calls.
The heterogeneity of the MCI group of participants
also represents a possible limitation of the present study.
Although biomarkers such as CSF and PiB-PET can help
differentiate MCI participants who have an AD-like profile
from those who have a normal profile, this data was only
available for a small number of ADNI-1 participants which
would have limited power to detect differences in CNVs.
In the next phases of the project (ADNI-GO and ADNI-2),
all subjects will have CSF and amyloid PET data, enabling
further examination of this issue.
5. Conclusion
In sum, we have conducted an initial CNV analysis in the
ADNI cohort dataset. Although no excess CNV burden was
found in cases relative to controls, a number of interesting
candidate genes and regions were identified. Replication in
larger samples will be critical to confirm these findings.
Additional region-based analyses may help elucidate the
role of these CNVs, and deep resequencing studies may be
warranted for some of these regions if they replicate in other
cohorts.
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